Athersys Fails Stroke Trial In Mid-Stage Study
April 17, 2015 at 13:02 PM EDT
Shares of Athersys are down almost 50% on the news of failing a phase 2 trial for stroke with the company using its multistem cell therapy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.